Welcome to our dedicated page for COGNITION THERAPEUTICS SEC filings (Ticker: CGTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cognition Therapeutics, Inc. filings document a clinical-stage biopharmaceutical issuer developing zervimesine for neurodegenerative diseases. Its Form 8-K reports cover financial results, Regulation FD presentations, clinical-development announcements, FDA meeting disclosures, and material agreements, including an at-the-market common-stock sales arrangement.
Proxy materials disclose annual meeting and stockholder voting matters, while registration and current-report disclosures identify the company’s Delaware corporate status, emerging growth company reporting status, and Nasdaq-listed common stock. The filings also provide formal records of capital-structure activity, governance processes, and risk areas associated with clinical research, regulatory review, grant funding, and the financing needs of a development-stage biotechnology company.
Cognition Therapeutics is a clinical-stage biopharmaceutical company developing small‑molecule therapies for age‑related CNS disorders. Its lead candidate zervimesine (CT1812) has multiple Phase 2 programs: the NIA‑funded START trial in 545 MCI/early Alzheimer’s patients is fully enrolled, while prior SHINE and SHIMMER studies met safety endpoints and showed biomarker‑linked cognitive and behavioral benefits that are informing planned Phase 3 Alzheimer’s and pivotal DLB psychosis trials in consultation with the FDA and EMA.
For the six months ended June 30, 2026, Cognition reported a net loss of $8,502 (in thousands) versus $15,214 (in thousands) a year earlier, driven by lower research and development expenses of $11,217 (in thousands) compared with $22,267 (in thousands) as large NIA‑funded trials advanced. Grant income declined to $7,497 (in thousands) in line with reduced reimbursable costs. Cash, cash equivalents and restricted cash totaled $34,762 (in thousands) at June 30, 2026, supplemented by approximately $21.6 million of remaining obligated NIA funds and $68.1 million of unused capacity under a 2025 at‑the‑market equity program. Management states these resources are expected to fund operations into the fourth quarter of 2027, assuming no additional ATM usage.
Cognition Therapeutics, Inc. reported second-quarter 2026 results and a business update centered on its lead candidate zervimesine (CT1812) for neurodegenerative disorders. Management highlighted progress in FDA discussions that clarified key elements of a planned Phase 3 trial in dementia with Lewy bodies psychosis, targeted to start in mid-2027 using an improved tablet formulation.
As of June 30, 2026, the company held approximately $34.8 million in cash, cash equivalents and restricted cash, plus $21.6 million in remaining obligated grant funding from the National Institute of Aging, and expects this to fund operations into the fourth quarter of 2027. Second-quarter research and development expenses were $5.1 million, down from $11.5 million a year earlier, while general and administrative expenses were $2.6 million versus $2.5 million. Net loss narrowed to $3.9 million, or $(0.04) per share, compared with $6.7 million, or $(0.11) per share in the prior-year quarter. The company also noted allowance of a new composition-of-matter patent for zervimesine, extending intellectual property protection.
Cognition Therapeutics announced that the FDA provided written feedback aligning on key aspects of a pivotal Phase 3 trial of zervimesine (CT1812) for psychosis in dementia with Lewy bodies (DLB). The FDA agreed that DLB psychosis can be an approvable outcome to support a New Drug Application.
The planned registrational program is expected to begin in mid-2027 and will randomize people with DLB psychosis to receive 100 mg once-daily oral zervimesine or placebo for nine months, including patients on stable off-label antipsychotics. The company is working with the FDA to use the neuropsychiatric inventory (NPI) as a novel primary endpoint.
The study builds on Phase 2 SHIMMER data, where zervimesine showed improvements in psychosis symptoms versus placebo and, in a recent analysis, slowed progression of hallucinations and delusions by 89%. Cognition highlights a significant unmet need, noting that up to 80% of DLB patients experience psychosis and no drugs are currently approved for DLB.
Khattar Jack A. reported acquisition or exercise transactions in this Form 4 filing.
Cognition Therapeutics Inc. director Jack A. Khattar received an equity award of 25,000 restricted stock units (RSUs). Each RSU represents the right to receive one share of common stock upon settlement. The RSUs vest in full on the earlier of June 17, 2027 or the company’s next annual stockholders’ meeting, contingent on his continued board service. Following this grant, Khattar directly holds 73,500 shares of common stock.
Monia Brett P reported acquisition or exercise transactions in this Form 4 filing.
Cognition Therapeutics Inc. director Brett P. Monia received an award of 25,000 restricted stock units (RSUs). These RSUs represent a right to receive an equal number of common shares at no purchase price per share.
The RSUs vest in full on the earlier of June 17, 2027 or the date of the company’s next annual meeting of stockholders, as long as Monia continues to serve as a director through that date. Following this grant, Monia directly holds 73,500 shares of Cognition Therapeutics common stock.
Wallace Peggy reported acquisition or exercise transactions in this Form 4 filing.
Cognition Therapeutics director Peggy Wallace received an equity grant tied to future stock. She was awarded 25,000 restricted stock units (RSUs), each representing a contingent right to receive one share of common stock. The RSUs vest in full on the earlier of June 17, 2027, or the company’s next annual stockholder meeting, if she continues serving as a director. Following this grant, her directly held position reported in the filing is 111,461 shares. This is a compensation-related award rather than an open-market purchase.
Cognition Therapeutics director Ellen B. Richstone reported a grant of 25,000 restricted stock units (RSUs). Each RSU represents the right to receive one share of common stock upon settlement. The RSUs vest in full on the earlier of June 17, 2027 or the company’s next annual stockholder meeting, contingent on her continued board service. Following this equity award, she holds 83,500 shares of common stock directly. This Form 4 reflects a compensation-related acquisition rather than any open-market trading.
Fletcher Aaron G.L. reported acquisition or exercise transactions in this Form 4 filing.
Cognition Therapeutics Inc. director Aaron G.L. Fletcher received an award of 25,000 restricted stock units (RSUs), each representing a contingent right to one share of common stock. The RSUs vest in full on the earlier of June 17, 2027 or the company’s next annual stockholder meeting, subject to his continued board service.
The filing shows 81,229 common shares held directly after the award, and additional indirect holdings through multiple Bios-affiliated investment funds. Under existing agreements, Fletcher holds certain equity awards as a nominee for BP Directors, LP, and various Bios and Cavu entities may be deemed indirect beneficial owners, while all reporting persons disclaim beneficial ownership beyond any pecuniary interest.
Cognition Therapeutics, Inc. held its Annual Meeting of Stockholders on June 17, 2026, conducted virtually. Stockholders elected Aaron Fletcher, Ph.D., and Lisa Ricciardi as Class II directors to serve until the 2029 Annual Meeting and until their successors are elected or appointed.
Fletcher received 15,093,537 votes for and 680,677 withheld, while Ricciardi received 15,094,238 votes for and 679,976 withheld, with 34,035,661 broker non-votes for each. Stockholders also ratified Ernst & Young LLP as the independent registered public accounting firm for the 2026 fiscal year, with 49,039,407 votes for, 126,951 against, and 643,517 abstentions.
Cognition Therapeutics, Inc. furnished an investor presentation under Regulation FD, outlining its strategy as a clinical-stage CNS drug developer focused on zervimesine (CT1812). The company highlights Dementia with Lewy bodies (DLB) psychosis as its lead indication, with a Phase 3 registrational trial in development following the SHIMMER Phase 2 study.
As of March 31, 2026, Cognition reports approximately $31 million in cash, equivalents and restricted cash, $25 million in obligated NIA grant funds, and a cash runway into Q2 2027 based on its current operating plan. The presentation notes more than $170 million in cumulative NIH/NIA grant support and a workforce of about 14 employees.
The deck describes SHIMMER Phase 2 results in DLB, including slowing of neuropsychiatric decline on the NPI-12 measure versus placebo, and plans for a 9‑month registrational study in DLB psychosis overseen by the FDA’s Division of Psychiatry. It also details Alzheimer’s programs, including the completed SHINE Phase 2 trial and the ongoing 545‑patient START trial in MCI through mild Alzheimer’s disease funded by an $81 million NIA grant.